Navigation Links
Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years
Date:8/5/2008

Long-Term Clinical Study Confirms Effectiveness of Autologous Therapy

DUSSELDORF, Germany, August 5 /PRNewswire/ -- The results of a two-year representative study of knee osteoarthritis, published in the internationally renowned journal "Osteoarthritis and Cartilage", confirm the safety and effectiveness of Orthokine therapy, in which anti-inflammatory proteins obtained from the patient's own blood are injected into the arthritic joint.

Researchers at Heinrich Heine University in Dusseldorf compared three treatments to determine which one produces the best long-term results for treatment of knee osteoarthritis. A total of 310 patients received a series of injections one of Orthokine, hyaluronic acid (a joint lubricant), or a placebo (table salt solution). Because of the chronic nature of arthritis, long-term treatment effects are particularly important for sufferers.

Two years after the initial treatment, 188 of the 310 patients were still experiencing reduced pain and improved function of the affected joint. The Orthokine group had the fewest patients who went on to seek further treatment. Patients who received Orthokine treatment had the greatest improvements in VAS and WOMAC scores. For the WOMAC test in particular, the outcomes were as follows: Starting from an initial WOMAC score of 124, the Orthokine group saw a reduction to a score of 58, while the final WOMAC scores for the other two groups remained well above that at 88 and 84. "This study shows that Orthokine treatment is a safe alternative to conventional methods", says study physician Carsten Moser.

"Osteoarthritis and Cartilage" is a respected scientific journal (impact factor 4.017) that publishes only original, peer-reviewed research into new methods for the treatment of diseases of the locomotor system.

Further information:

Orthogen AG

Frau Daniele Voss

Graf-Adolf-Str. 41

40210 Dusseldorf

Tel.: +49(0)211-60-255-35

Fa
'/>"/>

SOURCE Orthogen AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July ... ), a leading global pharmaceutical company, and Oculeve, a ... for dry eye disease, today announced that they have ... Oculeve in an all-cash transaction.  Under the terms of ... million upfront payment and commercialization milestone payments related to ...
(Date:7/6/2015)... -- China Information Technology, Inc. (the "Company" or "CNIT") ... platform, exchange, and big data solutions in ... its mobile app for Healthcare One Pass, ushering in ... devices. The Company jointly hosted the launch ceremony with ... Shenzhen News Net.   The mobile app for ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... ... Anticancer Drug, HOUSTON, ... to families, workplaces and communities, and many,Houstonians are aware of ... the CHRISTUS Stehlin Foundation for,Cancer Research, a nationally recognized leader ...
Journalists and other readers should disregard the news release "Oramed,Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository",OTC:ORMP, issued earlier today. The release was transmitted...
Cached Medicine Technology:Local Research Foundation Achieves Milestone in Fight Against Cancer 2Local Research Foundation Achieves Milestone in Fight Against Cancer 3
(Date:7/7/2015)... , ... July 07, 2015 , ... ... Ellen Purdy as the company’s new Chief Financial Officer, effective July 6th, 2015. ... experience in companies ranging from a multi-billion dollar, global chemical company to early ...
(Date:7/7/2015)... Annapolis, MD (PRWEB) , ... July 07, 2015 ... ... quality and an official accrediting body as designated by the Centers for Medicare ... improved user experience and to enhance compatibility with mobile devices. , The most ...
(Date:7/7/2015)... ON (PRWEB) , ... July 07, 2015 , ... On ... is effective immediately and permits the use of gluten-free claims for gluten free oats ... prospect of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free oat ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces today ... by the White House as a “Champion of Change” for Precision Medicine on ... the Champions of Change program recognizes Gleason and eight other extraordinary individuals who ...
(Date:7/6/2015)... ... July 06, 2015 , ... For over twenty years, Doctors ... injury victims. Throughout the company’s history the goal has been to be a ... in their recovery. And while Doctors on Liens has certainly achieved that goal, ...
Breaking Medicine News(10 mins):Health News:Office Practicum Announces new CFO 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... City Hotel and Casino will host the 3rd ... ReceptionATLANTIC CITY, N.J., Feb. 17 The American ... are teaming up on Wednesday, February 25, 2009 ... Blood Donor Campaign awards reception.(Logo: http://www.newscom.com/cgi-bin/prnh/20090217/DC71647LOGO ...
... Six studies published in the past year by a Cornell ... -- as well as daily helpings of other fruits and ... one of his recent papers, published in the Journal ... Cornell associate professor of food science and a member of ...
... (Feb. 17, 2009) A research project at Rice ... long-standing medical mystery that may link cardiovascular disease, osteoporosis and ... thank the rat. , The recent paper in Artery ... team reports they have found that common rats with a ...
... TORONTO, Feb. 17 /PRNewswire/ - Sentinelle Medical Inc., ... software and Siemens Healthcare today announced an OEM ... agreement, Siemens will sell the "Sentinelle Vanguard for ... Espree, MAGNETOM(R) Avanto and MAGNETOM(R) Symphony, A Tim(TM) ...
... by wartime conditions, researchers say , , TUESDAY, Feb. 17 ... can be exacerbated by combat conditions in Iraq and ... being evacuated for treatment, a new report finds. , ... responsible for poor morale and combat ineffectiveness, the researchers ...
... from The University of Nottingham are taking to the streets ... are nearly twice the national average. , Reducing high levels ... which ranks third highest in the country after Corby and ... Control Studies and Professor in Health Policy and Promotion at ...
Cached Medicine News:Health News:The American Red Cross Recognizes Atlantic City Casinos 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:Mutant rats offer clues to medical mystery 2Health News:Mutant rats offer clues to medical mystery 3Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 2Health News:Sentinelle Medical Enters OEM Distribution Agreement with Siemens AG 3Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3Health News:Investigating a community where smoking rates are double the national average 2
... Split Splint reduces PIP joint or DIP joint ... to put on. Soft gel-lining cushions injured fingers ... begin earlier for faster, more successful therapy results. ... and at night to maintain gains in motion. ...
... FoamWrap Final Flexion Wraps restore full PIP ... or when lost due to arthritic changes. ... foam-lined material hugs the finger to prevent ... restore motion. One size. Sold in packages ...
One splint does it all....
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
Medicine Products: